![]() All links to the ProviderPortal and clinical guideline pages will remain active and will be redirected. Will the AIM corporate website URL be changed? AIM’s corporate website will be moved to. Providers may continue to see the AIM company name on our websites for some time, but it’s expected that these will be changed through scheduled content update cycles. Will AIM references on BCBSIL’s website be changed? Changes will be ongoing. ![]() ![]() Access changes are not needed or planned however, all references to the AIM company name will eventually be updated to Carelon Medical Benefits Management. Will there be any changes for providers who connect with AIM via other means such as Availity Essentials? No. References to AIM within recorded scripting will be replaced with Carelon Medical Benefits Management. Will there be any changes to the AIM Clinical Guidelines URL or content? Yes, the clinical guidelines site will be automatically redirected to a new Carelon URL, and the branding will be updated to reflect Carelon.Īre any phone number changes planned as part of this transition? No, inbound phone numbers are not being changed. Will there be changes to how prior authorization requests are submitted or processed? No, there will be no changes to the case submission process. ![]() The AIM logo will be replaced with a Carelon logo. Will the AIM ProviderPortal URL or platform name be changed? No, the website address will not be affected all providers will continue to have access to. You will continue to follow your normal processes, use the same phone numbers and web addresses, including the AIM ProviderPortal, that you currently use for utilization management with BCBSIL. See below for other frequently asked questions. You will notice this name change: Carelon Medical Benefits Management (formerly known as AIM Specialty Health). They are associated with a reduced cost of care without compromising quality of care.AIM Specialty Health (AIM) has changed its name to Carelon Medical Benefits Management (Carelon) effective March 1, 2023.įollowing this change, Blue Cross and Blue Shield of Illinois (BCBSIL) will be making updates on our website to our utilization management page and related resources. Pathway regimens for breast cancer demonstrate an example of high-value care. The two cohorts had similar rates of hospitalization and emergency department visits however, the rate of granulocyte colony-stimulating factor use was significantly lower in the on-pathway cohort (72.5% in the on-pathway cohort v 82.8% in the off-pathway cohort odds ratio, 0.55 P ≤. Patients in both cohorts had a similar age distribution (median age, 52 years in the off-pathway cohort v 53 years in the on-pathway cohort), and most presented with stage II disease (49.4% in the off-pathway cohort v 49.8% in the on-pathway cohort) nearly two thirds of each cohort had hormone receptor positive cancer (67.3% in the off-pathway cohort v 64.9% in the on-pathway cohort). There were 959 patients in each cohort after matching. We compared post-6-month quality-of-care outcomes including hospitalization, emergency department visits, need for supportive drugs such as granulocyte colony-stimulating factor, and cost outcomes between the cohorts. On the basis of demographic and clinical characteristics, patients receiving a pathway regimen (on-pathway cohort) were matched to those who did not (off-pathway cohort) using 1:1 propensity score matching. Using nationally representative claims data from Anthem, together with clinical data from its Cancer Care Quality Program, we identified patients with breast cancer for whom chemotherapy was initiated between January 2015 and October 2016. There are few real-world data to support the value of such regimens, especially for patients with breast cancer. Pathway regimens are value-driven, evidence-based therapies that aim at high-quality, affordable cancer care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |